Targeting P2X7 receptors as a means for treating retinal disease

Erica L. Fletcher; Anna Y. Wang; Andrew I. Jobling; Matthew V. Rutar; Ursula Greferath; Ben Gu; Kirstan A. Vessey

doi:10.1016/j.drudis.2019.03.029

Targeting P2X7 receptors as a means for treating retinal disease

Erica L. Fletcher, Anna Y. Wang, Andrew I. Jobling, Matthew V. Rutar, Ursula Greferath, Ben Gu, Kirstan A. Vessey

Research output: Contribution to journal › Review article › peer-review

23 Citations (Scopus)

Abstract

Age-related macular degeneration and glaucoma are the commonest causes of irreversible vision loss in industrialized countries. The purine ATP is known to regulate a range of cellular functions in the retina via its action on P2 receptors, especially the P2X7 receptor. Although agents that attenuate P2X7 receptor function have been in development for many years, no compound is currently approved for the treatment of eye disease. However, newer compounds that cross the blood–brain barrier could have potential to reduce vision loss. This review will outline recent information relating to the role of P2X7 in age-related macular degeneration and glaucoma and, subsequently, we will discuss recent developments for attenuating P2X7 receptor function.

Original language	English
Pages (from-to)	1598-1605
Number of pages	8
Journal	Drug Discovery Today
Volume	24
Issue number	8
DOIs	https://doi.org/10.1016/j.drudis.2019.03.029
Publication status	Published - Aug 2019
Externally published	Yes

Access to Document

10.1016/j.drudis.2019.03.029

Cite this

@article{45627d551b564a51ab70f2adb5c05586,

title = "Targeting P2X7 receptors as a means for treating retinal disease",

abstract = "Age-related macular degeneration and glaucoma are the commonest causes of irreversible vision loss in industrialized countries. The purine ATP is known to regulate a range of cellular functions in the retina via its action on P2 receptors, especially the P2X7 receptor. Although agents that attenuate P2X7 receptor function have been in development for many years, no compound is currently approved for the treatment of eye disease. However, newer compounds that cross the blood–brain barrier could have potential to reduce vision loss. This review will outline recent information relating to the role of P2X7 in age-related macular degeneration and glaucoma and, subsequently, we will discuss recent developments for attenuating P2X7 receptor function.",

author = "Fletcher, {Erica L.} and Wang, {Anna Y.} and Jobling, {Andrew I.} and Rutar, {Matthew V.} and Ursula Greferath and Ben Gu and Vessey, {Kirstan A.}",

note = "Funding Information: This work was supported by the National Health and Medical Research Council of Australia (#1061418 to E.L.F. and A.I.J.; #1061419 to E.L.F. and K.A.V.). Funding Information: This work was supported by the National Health and Medical Research Council of Australia ( #1061418 to E.L.F. and A.I.J.; #1061419 to E.L.F. and K.A.V.). Publisher Copyright: {\textcopyright} 2019 Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = aug,

doi = "10.1016/j.drudis.2019.03.029",

language = "English",

volume = "24",

pages = "1598--1605",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - Targeting P2X7 receptors as a means for treating retinal disease

AU - Fletcher, Erica L.

AU - Wang, Anna Y.

AU - Jobling, Andrew I.

AU - Rutar, Matthew V.

AU - Greferath, Ursula

AU - Gu, Ben

AU - Vessey, Kirstan A.

N1 - Funding Information: This work was supported by the National Health and Medical Research Council of Australia (#1061418 to E.L.F. and A.I.J.; #1061419 to E.L.F. and K.A.V.). Funding Information: This work was supported by the National Health and Medical Research Council of Australia ( #1061418 to E.L.F. and A.I.J.; #1061419 to E.L.F. and K.A.V.). Publisher Copyright: © 2019 Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/8

Y1 - 2019/8

N2 - Age-related macular degeneration and glaucoma are the commonest causes of irreversible vision loss in industrialized countries. The purine ATP is known to regulate a range of cellular functions in the retina via its action on P2 receptors, especially the P2X7 receptor. Although agents that attenuate P2X7 receptor function have been in development for many years, no compound is currently approved for the treatment of eye disease. However, newer compounds that cross the blood–brain barrier could have potential to reduce vision loss. This review will outline recent information relating to the role of P2X7 in age-related macular degeneration and glaucoma and, subsequently, we will discuss recent developments for attenuating P2X7 receptor function.

AB - Age-related macular degeneration and glaucoma are the commonest causes of irreversible vision loss in industrialized countries. The purine ATP is known to regulate a range of cellular functions in the retina via its action on P2 receptors, especially the P2X7 receptor. Although agents that attenuate P2X7 receptor function have been in development for many years, no compound is currently approved for the treatment of eye disease. However, newer compounds that cross the blood–brain barrier could have potential to reduce vision loss. This review will outline recent information relating to the role of P2X7 in age-related macular degeneration and glaucoma and, subsequently, we will discuss recent developments for attenuating P2X7 receptor function.

UR - http://www.scopus.com/inward/record.url?scp=85064646602&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2019.03.029

DO - 10.1016/j.drudis.2019.03.029

M3 - Review article

C2 - 30954685

AN - SCOPUS:85064646602

SN - 1359-6446

VL - 24

SP - 1598

EP - 1605

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 8

ER -

Targeting P2X7 receptors as a means for treating retinal disease

Abstract

Access to Document

Other files and links

Cite this